Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians - Tập 72 Số 6 - Trang 524-541 - 2022
Angela N. Giaquinto1, Hyuna Sung1, Kimberly D. Miller1, Joan L. Kramer2, Lisa A. Newman3, Adair K. Minihan1, Ahmedin Jemal1, Rebecca L. Siegel1
1Surveillance and Health Equity Science, American Cancer Society Atlanta Georgia USA
2Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA
3Department of Surgery New York-Presbyterian, Weill Cornell Medicine New York New York USA

Tóm tắt

Abstract

This article is the American Cancer Society’s update on female breast cancer statistics in the United States, including population‐based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010–2019), the rate increased by 0.5% annually, largely driven by localized‐stage and hormone receptor‐positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989–2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016–2020) and two‐fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5‐year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black–White gaps in absolute terms for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative disease (88% vs. 96%), hormone receptor‐negative/human epidermal growth factor receptor 2‐positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21718

10.3322/caac.21695

10.3322/caac.21440

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER Research Data with Delay‐Adjustment 8 Registries Malignant Only November 2021 Submission (1975–2019)—Linked To County Attributes—Time Dependent (1990–2019) Income/Rurality 1969–2020 Counties. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute;2022. Accessed July 1 2022.seer.cancer.gov

10.3322/caac.21388

10.1007/978-0-387-88441-7

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER Research Data 17 Registries November 2021 Submission (2000–2019)—Linked To County Attributes—Time Dependent (1990–2019) Income/Rurality 1969–2020 Counties. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute;2022. Accessed July 1 2022.seer.cancer.gov

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER Research Limited‐Field Data 22 Registries November 2021 Submission (2000–2019)—Linked To County Attributes—Time Dependent (1990–2019) Income/Rurality 1969–2020 Counties. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute;2022. Accessed July 1 2022.seer.cancer.gov

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER Research Limited‐Field Data with Delay‐Adjustment 22 Registries Malignant Only November 2021 Submission (2000–2019)—Linked To County Attributes—Time Dependent (1990–2019) Income/Rurality 1969–2020 Counties. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute;2022. Accessed July 1 2022.seer.cancer.gov

North American Association of Central Cancer Registries (NAACCR). SEER*Stat Database: NAACCR Incidence Data—Cancer in North America Analytic File 1995–2019 for the NAACCR Hispanic/Latino Identification Algorithm (NHIA v2) Origin Custom File With County American Cancer Society Facts and Figures Projection Project (which includes data from the Centers for Disease Control and Prevention's National Program of Cancer Registries [NPCR] the Canadian Cancer Registry’s Provincial and Territorial Registries and the National Cancer Institute’s Surveillance Epidemiology and End Results [SEER] Registries; certified by the NAACCR as meeting high‐quality incidence data standards for the specified time periods). NAACCR; 2021.

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Mortality—All Causes of Death Aggregated With State Total U.S. (1990–2020) <Katrina/Rita Population Adjustment>. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute;2022. Underlying mortality data provided by the National Center for Health Statistics. Accessed July 1 2022.seer.cancer.gov

Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Mortality—All Causes of Death Aggregated With State Total U.S. (1969–2019) <Katrina/Rita Population Adjustment>. Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute; 2021. Underlying mortality data provided by the National Center for Health Statistics. Accessed July 1 2022.seer.cancer.gov

10.3322/caac.21731

American College of Surgeons Commission on Cancer.National Cancer Database 2019 Data Submission. American College of Surgeons Commission on Cancer;2021.

10.1245/s10434-019-07213-1

Centers for Disease Control and Prevention, 2019, Behavioral Risk Factor Surveillance System Survey Data 2019

National Center for Health Statistics.National Health Interview Surveys 2019(public‐use data file and documentation). National Center for Health Statistics Centers for Disease Control and Prevention; 2022. Accessed July 1 2022.cdc.gov/nchs/nhis/data‐questionnaires‐documentation.htm

10.3322/caac.21708

10.1093/jnci/djr257

Surveillance Research Program National Cancer Institute. SEER*Stat Software. Version 8.4.0. National Cancer Institute;2022.

National Cancer Institute. Joinpoint Regression Program. Version 4.9.1.0. Statistical Research and Applications Branch National Cancer Institute;2022. Accessed August 15 2022.surveillance.cancer.gov/joinpoint

National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.8.0. Statistical Research and Applications Branch National Cancer Institute;2022. Accessed July 1 2022.surveillance.cancer.gov/devcan

Arias E, 2021, Mortality profile of the non‐Hispanic American Indian or Alaska Native population, 2019, Natl Vital Stat Rep., 70, 1

10.1002/cncr.32472

10.1093/jnci/djac158

10.1200/OP.20.00831

10.1158/1055-9965.EPI-20-1528

10.1002/cncr.32207

10.3322/caac.21703

10.1186/s13058-021-01483-y

10.1158/1055-9965.EPI-20-1055

10.1007/s10549-020-05545-1

10.1007/s10552-016-0793-7

10.1002/cncr.32293

10.1007/s10549-017-4229-1

10.1158/0008-5472.CAN-18-0502

10.1016/j.canep.2018.11.006

10.1093/jnci/djv048

10.1158/1055-9965.EPI-16-0721

10.1001/jamasurg.2017.0005

10.1001/jamaoncol.2017.0595

10.1002/cncr.25679

10.1007/s10552-009-9437-5

10.1056/NEJMsr070105

10.1158/1055-9965.EPI-11-0061

10.1093/jnci/djab131

10.1158/1055-9965.EPI-18-0098

10.1093/jnci/djv159

10.1093/jnci/djab186

10.1007/s10549-018-5042-1

10.1158/1055-9965.EPI-20-1784

Hamilton BE, 2022, Births: Provisional Data for 2021. Vital Statistics Rapid Release Report No. 20. Division of Vital Statistics, National Center for Health, Statistics

10.1158/1055-9965.EPI-20-0924

10.1056/NEJMoa050518

10.1093/jnci/dju289

10.3389/fonc.2018.00227

10.1158/1055-9965.EPI-17-0945

10.1002/cncr.33121

10.1158/1055-9965.EPI-20-1038

10.1056/NEJMp2200244

10.1097/MLR.0000000000000417

10.1001/jamasurg.2014.2895

10.1097/PRS.0000000000001276

10.1007/s10549-012-2156-8

10.1245/s10434-009-0635-x

10.1001/jamasurg.2017.0115

10.1016/j.jamcollsurg.2019.12.004

American Society of Breast Surgeons.Consensus Guideline on Diagnostic and Screening Magnetic Resonance Imaging of the Breast. American Society of Breast Surgeons;2017.

10.3322/caac.21149

10.1016/j.jss.2020.12.057

10.1002/jso.25315

10.1001/jamasurg.2020.0322

10.1016/j.semradonc.2022.01.004

10.1200/JCO.2012.45.2615

Society of Surgical Oncology.Choosing Wisely. Society of Surgical Oncology; 2021. Accessed August 8 2022.choosingwisely.org/clinician‐lists/sso‐sentinel‐node‐biopsy‐in‐node‐negative‐women‐70‐and‐over

10.1056/NEJMoa1804710

10.1093/jnci/djaa148

10.1245/s10434-018-6531-5

10.1200/JCO.20.03399

10.1056/NEJMoa1612645

10.1056/NEJMoa1814017

10.1001/jama.2018.19323

10.1056/NEJMoa1910549

10.1056/NEJMoa2112651

10.1080/14728214.2021.1916468

10.1007/s10549-022-06547-x

10.1200/JCO.21.02006

10.1016/j.annonc.2021.06.024

10.1056/NEJMoa2115022

10.1056/NEJMra1307118

10.1056/NEJMoa2203690

10.1200/JCO.22.00519

10.1093/jncimonographs/lgu016

10.1007/s10549-019-05403-9

10.1001/jama.2017.19130

10.1200/JOP.2017.023333

10.1002/cncr.34241

10.1001/jama.2014.17322

10.1200/JCO.2014.57.1349

10.1158/1055-9965.EPI-15-0243

MoubadderL CollinLJ NashR et al. Drivers of racial regional and socioeconomic disparities in late‐stage breast cancer mortality.Cancer. Published online July 22 2022. doi:10.1002/cncr.34391

10.1200/JCO.2017.73.7932

10.1001/jamaoncol.2022.0159

10.1001/jamaoncol.2021.1254

10.1002/cncr.25542

10.1001/jamaoncol.2015.3856

10.1001/jamasurg.2018.5113

10.1002/cncr.33527

American Cancer Society.Cancer Facts & Figures 2022. American Cancer Society; 2022. Accessed July 1 2022.cancer.org/research/cancer‐facts‐statistics/all‐cancer‐facts‐figures/cancer‐facts‐figures‐2022.html

10.1007/s11113-021-09647-6

10.1093/ije/dyl089

10.3322/caac.21442

10.1001/jama.2015.12783

American Cancer Society. Table 6B. Up‐to‐Date Mammography Prevalence (%) by State US 2020.Cancer Prevention & Early Detection Facts & Figures Tables and Figures 2022. American Cancer Society; 2022:32. Accessed July 1 2022.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/cancer‐prevention‐and‐early‐detection‐facts‐and‐figures/cped‐2022‐tables‐and‐figures.pdf

10.7326/M15-2886